Open AccessAccumulation of Major Linezolid Metabolites in Patients with Renal Impairment
Author(s) -
Ernane Souza,
Ryan L. Crass,
Jeremy Felton,
Kengo Hanaya,
Manjunath P. Pai
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00027-20
Subject(s) - linezolid , metabolite , medicine , renal function , pharmacology , gastroenterology , biology , staphylococcus aureus , bacteria , vancomycin , genetics
In patients with renal impairment ( n = 22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations ( r 2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.